COMMUNIQUÉS West-GlobeNewswire

Checkerspot and Huvepharma Partner to Commercialize Groundbreaking Human Milk Fat Analog
07/10/2025
Clearing a Major Technological Hurdle, Checkerspot & Huvepharma Ready to Scale Production of the Novel, Direct Analog for Human Milk Fat Alameda, Calif (USA) and Sofia (Bulgaria), Oct. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Ipsen - Septembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/10/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - September 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
07/10/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
07/10/2025
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and [...]
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
07/10/2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
07/10/2025
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
07/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
07/10/2025
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve [...]
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Jade Biosciences Announces $135 Million Private Placement
07/10/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
07/10/2025
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less [...]
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
07/10/2025
Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 [...]
Esaote enters the field of neurosurgery by presenting an innovative intraoperative MRI system
07/10/2025
I-Genius is the result of Esaote’s research and collaboration with neurosurgeons. The results achieved using MRI systems in brain glioma surgery were presented at EANS annual Congress held in Vienna The medical and [...]
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
07/10/2025
To release full third quarter 2025 financial results on November 13th; conference call to follow TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a [...]
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
07/10/2025
ROCKVILLE, Md. and SUZHOU, China, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”), a global, commercial stage, integrated [...]
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
07/10/2025
Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readiness BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage [...]
Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025
07/10/2025
REDWOOD CITY, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver [...]
TerrAscend to Host Third Quarter 2025 Earnings Conference Call
07/10/2025
TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that it will host a scheduled [...]
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
07/10/2025
BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]

Pages